SAB BiotherapeuticsSABS 26 3-Year ROIIC % is -48.82 as of Dec. 2025. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,319 Biotechnology companies, SAB Biotherapeutics ranks worse than 64.9% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
SAB Biotherapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -48.82%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for SAB Biotherapeutics's 3-Year ROIIC % or its related term are showing as below:
SABS's 3-Year ROIIC % is ranked worse than 64.9% of 1319
companies
in the Biotechnology industry
Industry Median: -4.44
vs SABS: -48.82
SAB Biotherapeutics (NAS:SABS) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
SAB Biotherapeutics 3-Year ROIIC % Related Terms
SAB Biotherapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for SAB Biotherapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SABS vs SRZN, GLSI, ZNTL: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, SAB Biotherapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SAB Biotherapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where SAB Biotherapeutics's 3-Year ROIIC % falls into.
SAB Biotherapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -48.953 (Dec. 2025) - -28.918 (Dec. 2022) )
/
( 72.708 (Dec. 2025) - 31.666 (Dec. 2022) )
=
-20.035
/
41.042
=
-48.82%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
SAB Biotherapeutics (SABS) has a 3-Year ROIIC % of -48.82 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on SAB Biotherapeutics and its competitors. According to the industry distribution chart, SAB Biotherapeutics ranks #856 out of 1319 companies in the Biotechnology industry, placing it in the top 64.9%.
Is SAB Biotherapeutics' 3-Year ROIIC % too high?
SAB Biotherapeutics' current 3-Year ROIIC % is -48.82. Based on the distribution chart, SAB Biotherapeutics ranks #856 out of 1319 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' 3-Year ROIIC % compare to SRZN and GLSI?
According to the Biotechnology industry distribution chart, SAB Biotherapeutics ranks #856 out of 1319 companies for 3-Year ROIIC %. This places SAB Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current 3-Year ROIIC % is -48.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current 3-Year ROIIC % of -48.82. The current 3-Year ROIIC % is -48.82. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current 3-Year ROIIC % is -48.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score
Get the complete analysis for SABS
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SABS has been successfully added to your 
